Is miR-29 an oncogene or tumor suppressor in CLL?

Yuri Pekarsky; Carlo M. Croce

doi:10.18632/oncotarget.129

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Is miR-29 an oncogene or tumor suppressor in CLL?

Yuri Pekarsky _ and Carlo M. Croce

PDF | How to cite

Oncotarget. 2010; 1:224-227. https://doi.org/10.18632/oncotarget.129

Metrics: PDF 5335 views | ?

Abstract

Received: June 21, 2010, Accepted: July 7, 2010, Published: July 8, 2010

B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH VH; indolent CLL shows low ZAP-70 expression and mutated IgH VH. We recently found that miR-29 is upregulated in indolent human B-CLL, compared to aggressive B-CLL and normal CD19+ B-cells. To determine the role of miR-29 in CLL, we generated transgenic mice overexpressing miR-29 in mouse B-cells. Recently we reported that miR-29 transgenic mice develop indolent CLL phenotype. Interestingly, our previous findings suggest that miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, indicating that miR-29 might function as a tumor suppressor in CLL. Here we discuss these results and provide additional insights into function of miR-29 in CLL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 129

Publication Alerts

Oncoscience

Post-Publication Promotion

Research Perspectives:

Is miR-29 an oncogene or tumor suppressor in CLL?

Abstract